NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/07/2026 14:36
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization642.5 mln
Float31.14 mln
Earnings Date05/06/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
7
/ 100
Severely lagging
Debt / Equity
0.01
Debt-free
ROE
-267
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
BridgeBio Oncology Therapeutics is a clinical-stage biotech company focused on developing oral drug treatments for several types of cancer, including lung, breast, and colorectal cancers. The company is advancing multiple drug candidates through early-stage clinical trials, each designed to target specific genetic mutations that drive tumor growth. Founded in 2016 and based in South San Francisco, California, BridgeBio Oncology aims to deliver more precise treatment options for cancer patients with limited alternatives.
